Results 241 to 250 of about 83,002 (289)
Revealing the invisible: a new imaging paradigm for α-synuclein pathology in Parkinson's disease. [PDF]
Meng J, Li X.
europepmc +1 more source
SCD2 Alleviates Diabetes‐Associated Cognitive Dysfunction by Improving Microglial Lipid Metabolism
This study reveals a novel mechanism of microglial metabolic dysfunction in diabetic cognitive impairment. Defective SCD2 disrupts monounsaturated fatty acid (MUFA) metabolism, triggering mitochondrial oxidative phosphorylation dysfunction and leading to abnormal lipid droplet accumulation (marked by PLIN2).
Yang Yang +5 more
wiley +1 more source
The cross-linking activity of transglutaminase 2 drives α-Synuclein pathology in synucleinopathy models. [PDF]
Hassanzadeh K +5 more
europepmc +1 more source
Summary Background The diagnosis and management of pituitary pars intermedia dysfunction (PPID) in horses includes evaluating abnormal plasma concentrations of adrenocorticotrophic hormone (ACTH). Treatment commonly includes the oral dopamine agonist pergolide mesylate, which suppresses the pathologic overproduction of ACTH.
A. Bracken +5 more
wiley +1 more source
Competing chaperone pathways in α-synuclein disaggregation and aggregation dynamics. [PDF]
Auld NK +4 more
europepmc +1 more source
Proteostasis of organelles in aging and disease
Cells rely on regulated proteostasis mechanisms to keep their internal compartments functioning properly. When these mechanisms fail, damaged proteins accumulate, disrupting organelles, such as the nucleus, mitochondria, endoplasmic reticulum, Golgi, and lysosomes, as well as membraneless organelles, such as stress granules, processing bodies, the ...
Yara Nabawi +5 more
wiley +1 more source
Pathogenic mechanism underlying parkinsonism induced by neurotoxicants (MPTP and 6-hydroxydopamine) and α-synuclein: a unifying hypothesis. [PDF]
Zhu BT.
europepmc +1 more source

